Lichen Planus, Oral Clinical Trial
— LICHENVIROfficial title:
Study of Inflammatory Role of Epstein-Barr Virus (EBV) in Atrophic and Erosive Forms of Oral Lichen Planus
| NCT number | NCT02276573 |
| Other study ID # | 14-AOI-02 |
| Secondary ID | |
| Status | Completed |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | March 30, 2015 |
| Est. completion date | March 10, 2016 |
| Verified date | November 2023 |
| Source | Centre Hospitalier Universitaire de Nice |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Oral lichen planus (OLP) is a chronic inflammatory and relapsing. The average prevalence is 1 to 4%. The clinics forms are many and symptoms are varied. The erosive form, painful and debilitating is characterized by erosive areas, ulcerated on an erythematous base with or without a keratinocyte lichenien network. The literature data moving towards an autoimmune origin, but the pathophysiological mechanisms of OLP remain unknown. This project represents the first part of a comprehensive project to examine the oral pathogenesis of different viruses (Herpes and papillomavirus HPV) and centered on Epstein-Barr Virus (EBV).
| Status | Completed |
| Enrollment | 13 |
| Est. completion date | March 10, 2016 |
| Est. primary completion date | March 10, 2016 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Patient = 18 years - Clinical and/or histological diagnosis of erosive or atrophic OLP - No signs of severe dysplasia at the sampling Exclusion Criteria: o immunosuppressive or anti-inflammatory therapies at the inclusion |
| Country | Name | City | State |
|---|---|---|---|
| France | Hôpital saint Roch | Nice |
| Lead Sponsor | Collaborator |
|---|---|
| Centre Hospitalier Universitaire de Nice |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Measure of level of EBV nucleic acids | day 1 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03320460 -
Photobiomodulation in Oral Lichen Planus
|
N/A | |
| Recruiting |
NCT06158113 -
Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept Study
|
Phase 2 | |
| Completed |
NCT03687437 -
Lichen Planus and Mean Platelet Volum
|
||
| Completed |
NCT00130572 -
Efficacy of Elidel Cream on Erosive Oral Lichen Planus
|
Phase 3 | |
| Completed |
NCT04673916 -
Treatment Protocols for Patients With Symptomatic Oral Lichen Planus
|
N/A | |
| Not yet recruiting |
NCT06362005 -
The Efficacy of Selenium as an Alternative or Complementary Topical Treatment of Oral Lichen Planus
|
Phase 4 | |
| Completed |
NCT00102557 -
Hydroxychloroquine vs. Clobetasol Rinse to Treat Oral Lichen Planus
|
Phase 2 | |
| Completed |
NCT00133107 -
Safety and Effectiveness of Efalizumab to Treat Oral Lichen Planus
|
N/A | |
| Completed |
NCT04718311 -
Study on Treatment for Patients With Symptomatic Oral Lichen Planus
|
N/A | |
| Recruiting |
NCT05330572 -
Clinical and Molecular Correlates of Response to First Line Treatment in Lichen Planus
|
||
| Completed |
NCT00656214 -
Treatmant of Oral Lichen Planus With Lycopene
|
Phase 2 | |
| Completed |
NCT04976673 -
Comparison of Clinical Efficiency of Photodynamic Therapy and Topical Corticosteroid in Treatment of Oral Lichen Planus
|
Phase 2 | |
| Completed |
NCT00746772 -
Efficacy of Purslane in Treatment of Oral Lichen Planus
|
Phase 2 |